ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 328,200 shares, a decline of 74.9% from the June 15th total of 1,310,000 shares. Based on an average daily volume of 18,890,000 shares, the days-to-cover ratio is currently 0.0 days.

ENDRA Life Sciences Price Performance

NASDAQ NDRA remained flat at $0.09 on Thursday. The company had a trading volume of 5,045,663 shares, compared to its average volume of 9,428,568. The business has a 50-day moving average price of $0.19 and a two-hundred day moving average price of $0.70. ENDRA Life Sciences has a twelve month low of $0.07 and a twelve month high of $2.79. The stock has a market capitalization of $6.32 million, a PE ratio of -0.07 and a beta of 0.82.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.26) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets dropped their price objective on shares of ENDRA Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, June 7th.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.